Patient-centered outcomes of a value-based insurance design program for patients with diabetes

Population Health Management

Volumn 16, Issue 2, 2013, Pages 99-106

  Elliott, Daniel J ^a,b   Robinson, Edmondo J ^a,b   Anthony, Karen B ^a   Stillman, Paula L ^c  

^a CHRISTIANA HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERGLYCEMIC AGENT; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH INSURANCE; HEALTH STATUS; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDY; SELF CARE; SELF REPORT; VALUE BASED INSURANCE DESIGN;

ADOLESCENT; ADULT; DELAWARE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FINANCING, PERSONAL; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT-CENTERED CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; VALUE-BASED PURCHASING; YOUNG ADULT;

EID: 84876148287     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2012.0031     Document Type: Article

References (46)

1. Claxton G, DiJulio B, Whitmore H, et al. Health benefits in 2010: Premiums rise modestly, workers pay more toward coverage. Health Aff (Millwood) 2010;29:1942-1950.
2. Landon BE, Rosenthal MB, Normand SL, et al. Incentive formularies and changes in prescription drug spending. Am J Manag Care 2007;13:360-369.
3. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006;12:509-517.
4. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 2007;298:61-69.
5. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-2232.
6. Gilman BH, Kautter J. Consumer response to dual incentives under multitiered prescription drug formularies. Am J Manag Care 2007;13:353-359.
7. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-429.
8. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. Int J Clin Pract 2008;62:76-87.
9. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530.
10. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood) 2007;26:w195-w203.
11. Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. Health Aff (Millwood) 2011;30:100-108.
12. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005;143:89-99.
13. Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood) 2007;26:186-194.
14. Chernew ME, Juster IA, Shah M, et al. Evidence that valuebased insurance can be effective. Health Aff (Millwood) 2010;29:530-536.
15. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood) 2010;29:1988-1994.
16. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood) 2011;30:109-117.
17. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood) 2010;29:1995-2001.
18. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008;27: 103-112.
19. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood) 2010;29:2002-2008.
20. Federal Coordinating Council for Comparative Effectiveness Research Report to the President and the Congress U.S. Department of Health and Human Services; June 30, 2009. Available at: http://www.hhs.gov/recovery/programs/cer/ cerannualrpt.pdf. Accessed June 27, 2012.
21. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615.
22. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002;25:23-29.
23. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-2559.
24. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
25. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-431.
26. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005; 28:59-64.
27. Tunceli K, Bradley CJ, Lafata JE, et al. Glycemic control and absenteeism among individuals with diabetes. Diabetes Care 2007;30:1283-1285.
28. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-2805.
29. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-564.
30. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: Results from 7 studies and a revised scale. Diabetes Care 2000;23:943-950.
31. Pierre-Jacques M, Safran DG, Zhang F, et al. Reliability of new measures of cost-related medication nonadherence. Med Care 2008;46:444-448.
32. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med 2006;21:267-275.
33. Cunny KA, Perri M 3rd. Single-item vs multiple-item measures of health-related quality of life. Psychol Rep 1991;69: 127-130.
34. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
35. Piette JD, Wagner TH, Potter MB, Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-109.
36. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: The treatments people forgo, how often, and who is at risk. Am J Public Health 2004;94:1782-1787.
37. Paez KA, Zhao L, Hwang W. Rising out-of-pocket spending for chronic conditions: A ten-year trend. Health Aff (Millwood) 2009;28:15-25.
38. Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: A longitudinal analysis. Med Care 2010;48:87-94.
39. Solomon MD, Goldman DP, Joyce GF, Escarce JJ. Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med 2009;169:740-748; discussion 748-749.
40. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 2008;168:271-276.
41. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008;23:588-594.
42. Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005;31:564-571.
43. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: Economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177-1180.
44. Soumerai SB, Mah C, Zhang F, et al. Effects of health maintenance organization coverage of self-monitoring devices on diabetes self-care and glycemic control. Arch Intern Med 2004;164:645-652.
45. Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff (Millwood) 2003;22:220-229.
46. Baicker K, Cutler D, Song Z. Workplace wellness programs can generate savings. Health Aff (Millwood) 2010;29:304-311.